Mylan, Aurobindo denied judgment against US states' antitrust claims over generic drugs
MLex Summary: Mylan and Aurobindo Pharma were denied reconsideration on summary judgments against states’ antitrust claims over generic drugs. US District Judge Michael P. Shea said the states are not, as...To view the full article, register now.
Already a subscriber? Click here to view full article